Unlabelled: The global burden of infections due to the pathogenic fungus is substantial in persons with low CD4 T cell counts. Previously, we deleted three chitin deacetylase genes from to create a chitosan-deficient, avirulent strain, designated which, when used as a vaccine, protected mice from challenge with virulent strain KN99. Here, we explored the immunological basis for protection. Vaccine-mediated protection was maintained in mice lacking B cells or CD8 T cells. In contrast, protection was lost in mice lacking α/β T cells or CD4 T cells. Moreover, CD4 T cells from vaccinated mice conferred protection upon adoptive transfer to naive mice. Importantly, while monoclonal antibody-mediated depletion of CD4 T cells just prior to vaccination resulted in complete loss of protection, significant protection was retained in mice depleted of CD4 T cells after vaccination, but prior to challenge. Vaccine-mediated protection was lost in mice genetically deficient in IFNγ, TNFα, or IL-23p19. A robust influx of leukocytes and IFNγ- and TNFα-expressing CD4 T cells was seen in the lungs of vaccinated and challenged mice. Finally, a higher level of IFNγ production by lung cells stimulated ex vivo correlated with lower fungal burden in the lungs. Thus, while B cells and CD8 T cells are dispensable, IFNγ and CD4 T cells have overlapping roles in generating protective immunity prior to vaccination. However, once vaccinated, protection becomes less dependent on CD4 T cells, suggesting a strategy for vaccinating HIV persons prior to loss of CD4 T cells.
Importance: The fungus is responsible for >100,000 deaths annually, mostly in persons with impaired CD4 T cell function such as AIDS. There are no approved human vaccines. We previously created a genetically engineered avirulent strain of , designated . When used as a vaccine, protects mice against a subsequent challenge with a virulent strain. Here, we defined components of the immune system responsible for vaccine-mediated protection. We found that while B cells and CD8 T cells were dispensible, protection was lost in mice genetically deficient in CD4 T cells, and the cytokines IFNγ, TNFα, or IL-23. A robust influx of cytokine-producing CD4 T cells was seen in the lungs of vaccinated mice following infection. Importantly, protection was retained in mice depleted of CD4 T cells following vaccination, suggesting a strategy to protect persons who are at risk for future CD4 T cell dysfunction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11195286 | PMC |
http://dx.doi.org/10.1101/2024.06.12.598760 | DOI Listing |
Am J Clin Pathol
January 2025
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Objectives: Immune checkpoint inhibitors have revolutionized treatment of platinum-refractory advanced bladder cancer, offering hope where options are limited. Response varies, however, influenced by factors such as the tumor's immune microenvironment and prior therapy. Muscle-invasive bladder cancer (MIBC) is stratified into molecular subtypes, with distinct clinicopathologic features affecting prognosis and treatment.
View Article and Find Full Text PDFASN Neuro
January 2025
Department of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond, Virginia, USA.
People living with HIV (PLWH) experience HIV-associated neurocognitive disorders (HAND), even though combination antiretroviral therapy (cART) suppresses HIV replication. HIV-1 transactivator of transcription (HIV-1 Tat) contributes to the development of HAND through neuroinflammatory and neurotoxic mechanisms. C-C chemokine 5 receptor (CCR5) is important in immune cell targeting and is a co-receptor for HIV viral entry into CD4+ cells.
View Article and Find Full Text PDFBrain metastasis (BM) is a poor prognostic factor in cancer patients. Despite showing efficacy in many extracranial tumors, immunotherapy with anti-PD-1 monoclonal antibody (mAb) or anti-CTLA-4 mAb appears to be less effective against intracranial tumors. Promisingly, recent clinical studies have reported that combination therapy with anti-PD-1 and anti-CTLA-4 mAbs has a potent antitumor effect on BM, highlighting the need to elucidate the detailed mechanisms controlling the intracranial tumor microenvironment (TME) to develop effective immunotherapeutic strategies.
View Article and Find Full Text PDFCancer Res
January 2025
Oregon Health & Science University, Portland, OR, United States.
Senescence is a non-proliferative, survival state that cancer cells can enter to escape therapy. In addition to soluble factors, senescence cells secrete extracellular vesicles (EVs), which are important mediators of intercellular communication. To explore the role of senescent cell-derived EVs (senEVs) in inflammatory responses to senescence, we developed an engraftment-based senescence model in wild-type mice and genetically blocked senEV release in vivo, without significantly affecting soluble mediators.
View Article and Find Full Text PDFDiscov Oncol
January 2025
Graduate School of Qinghai University, Xining, 810000, Qinghai Province, People's Republic of China.
The occurrence and progression of breast cancer (BCa) are complex processes involving multiple factors and multiple steps. The tumor microenvironment (TME) plays an important role in this process, but the functions of immune components and stromal components in the TME require further elucidation. In this study, we obtained the RNA-seq data of 1086 patients from The Cancer Genome Atlas (TCGA) database.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!